Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Jan 3.

Published in final edited form as: J Neuroimmunol. 2021 Sep 15;360:577721. doi: 10.1016/j.jneuroim.2021.577721

Table 4.

Summary of progressive Multifocal Leukoencephalopathy (PML) cases with different disease modifying therapies.

Medication	Total Cases of PML
Natalizumab	839^a
Fingolimod	40^b,e
Dimethyl Fumarate	11^a,e
Ocrelizumab	1^c,e
Alemtuzumab	1^d,e

The data is not published and was available on request by

^a

Biogen,

^b

Novartis,

^c

Genentech and

^d

Sanofi till September 2020.

^e

Cases of PML not attributable to prior natalizumab exposure.